[go: up one dir, main page]

PE20161220A1 - Formulaciones de pridopidina de liberacion modificada - Google Patents

Formulaciones de pridopidina de liberacion modificada

Info

Publication number
PE20161220A1
PE20161220A1 PE2016001263A PE2016001263A PE20161220A1 PE 20161220 A1 PE20161220 A1 PE 20161220A1 PE 2016001263 A PE2016001263 A PE 2016001263A PE 2016001263 A PE2016001263 A PE 2016001263A PE 20161220 A1 PE20161220 A1 PE 20161220A1
Authority
PE
Peru
Prior art keywords
modified release
pridopidine
dosage form
oral dosage
provides
Prior art date
Application number
PE2016001263A
Other languages
English (en)
Inventor
Merav Bassan
Ioana Lovinger
Daniella Licht
Laura Yehudit Guilatt
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of PE20161220A1 publication Critical patent/PE20161220A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La presente invencion proporciona una forma de dosificacion oral solida de liberacion modificada que comprende una cantidad terapeuticamente efectiva de pridopidina o una sal farmaceuticamente aceptable de la misma, y al menos un excipiente de control de velocidad farmaceuticamente aceptable, en donde la forma de dosificacion oral solida proporciona un perfil de concentracion de pridopidina en plasma in vivo que tiene una Cmax media de aproximadamente 1,400 ng/ml o menos. La presente invencion tambien proporciona un metodo para tratar a un individuo que padece de una enfermedad neurodegenerativa o enfermedad relacionada con dopamina, que comprende la administracion una vez al dia de una forma de dosificacion oral solida de liberacion modificada
PE2016001263A 2014-01-22 2015-01-21 Formulaciones de pridopidina de liberacion modificada PE20161220A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461930358P 2014-01-22 2014-01-22
US201462050626P 2014-09-15 2014-09-15

Publications (1)

Publication Number Publication Date
PE20161220A1 true PE20161220A1 (es) 2016-11-23

Family

ID=53543863

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001263A PE20161220A1 (es) 2014-01-22 2015-01-21 Formulaciones de pridopidina de liberacion modificada

Country Status (20)

Country Link
US (3) US20150202302A1 (es)
EP (2) EP4049657A1 (es)
JP (2) JP6949487B2 (es)
KR (1) KR102479759B1 (es)
CN (1) CN106170287A (es)
AU (1) AU2015209411A1 (es)
CA (1) CA2937243C (es)
CL (1) CL2016001874A1 (es)
DK (1) DK3096759T3 (es)
EA (1) EA201691454A1 (es)
ES (1) ES2911800T3 (es)
HU (1) HUE058288T2 (es)
IL (2) IL246598B (es)
MX (1) MX377576B (es)
PE (1) PE20161220A1 (es)
PL (1) PL3096759T3 (es)
TW (1) TW201605446A (es)
UA (1) UA122053C2 (es)
UY (1) UY35962A (es)
WO (1) WO2015112601A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CN103249697B (zh) 2010-09-03 2016-06-15 梯瓦制药国际有限责任公司 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
ES2879631T3 (es) 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2015112601A1 (en) 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
ES2930628T3 (es) 2015-02-25 2022-12-20 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la memoria
WO2017015615A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) * 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
BR112019003731A2 (pt) * 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
HUE058314T2 (hu) * 2016-09-16 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása Rett-szindróma kezelésére
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
JP7114604B2 (ja) 2017-01-20 2022-08-08 プリレニア ニューロセラピューティクス リミテッド 脆弱ｘ症候群の治療のためのプリドピジンの使用
EP4154882A1 (en) 2017-08-14 2023-03-29 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
EP3675830A1 (en) * 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
BR112020004622A2 (pt) 2017-09-08 2020-09-24 Prilenia Neurotherapeutics Ltd. pridopidina para tratamento de discinesias induzidas por droga
KR20200056071A (ko) 2018-11-14 2020-05-22 한화토탈 주식회사 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물
BR112021015346A2 (pt) * 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4020983B2 (ja) * 1995-07-07 2007-12-12 帝國製薬株式会社 持続性製剤およびその製法
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1283040A4 (en) 2000-03-21 2008-05-14 Nippon Shinyaku Co Ltd ORAL PREPARATIONS WITH PROLONGED RELEASE
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
GB0125088D0 (en) 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
DK1802573T3 (en) 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
CA2869145A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
ES2879631T3 (es) * 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
WO2015112601A1 (en) 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine

Also Published As

Publication number Publication date
US20190209542A1 (en) 2019-07-11
CA2937243C (en) 2023-07-18
WO2015112601A1 (en) 2015-07-30
KR102479759B1 (ko) 2022-12-21
MX377576B (es) 2025-03-04
EP4049657A1 (en) 2022-08-31
AU2015209411A1 (en) 2016-09-01
JP6949487B2 (ja) 2021-10-13
US20240041855A1 (en) 2024-02-08
PL3096759T3 (pl) 2022-06-13
IL246598B (en) 2021-01-31
US20150202302A1 (en) 2015-07-23
ES2911800T3 (es) 2022-05-20
IL280485B2 (en) 2023-05-01
EP3096759A4 (en) 2017-08-02
EP3096759A1 (en) 2016-11-30
MX2016009427A (es) 2016-12-08
JP2020023518A (ja) 2020-02-13
CA2937243A1 (en) 2015-07-30
TW201605446A (zh) 2016-02-16
CL2016001874A1 (es) 2017-05-12
CN106170287A (zh) 2016-11-30
UY35962A (es) 2015-08-31
HUE058288T2 (hu) 2022-07-28
UA122053C2 (uk) 2020-09-10
KR20160125385A (ko) 2016-10-31
IL246598A0 (en) 2016-08-31
JP7266298B2 (ja) 2023-04-28
JP2017503823A (ja) 2017-02-02
EP3096759B1 (en) 2022-04-06
EA201691454A1 (ru) 2017-01-30
DK3096759T3 (da) 2022-05-09
IL280485A (en) 2021-03-01
IL280485B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
PE20161220A1 (es) Formulaciones de pridopidina de liberacion modificada
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MX380798B (es) Profármacos de alvocidib que tienen una biodisponibilidad aumentada.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
BR112017028140A2 (pt) formulações farmacêuticas
MX2015010829A (es) Compuestos terapeuticos y sus usos.
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
WO2016106284A3 (en) Creatine prodrugs, compositions and methods of use thereof
UA115250C2 (uk) Фармацевтичні комбінації
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
PH12014500684A1 (en) Treatment of rhinitis
PH12016501975A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide

Legal Events

Date Code Title Description
FD Application declared void or lapsed